Novel chemotherapy approaches for cervical cancer

Cancer

Volumn 115, Issue 14, 2009, Pages 3166-3180

  Movva, Sujana ^a   Rodriguez, Lorna ^b   Arias Pulido, Hugo ^a   Verschraegen, Claire ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Adaptor proteins; Drug therapy; Epidermal growth factor receptor; Uterine cervical cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; SENAZOLE; TIRAPAZAMINE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINDESINE; WART VIRUS VACCINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ANGIOGENESIS; AREA UNDER THE CURVE; ASIAN; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CARCINOGENIC ACTIVITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG ERUPTION; DRUG MEGADOSE; EPIGENETICS; EXCISION; HUMAN; IMMUNOTHERAPY; ITALY; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL DECISION MAKING; META ANALYSIS; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; ONTOGENY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PATIENT CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SOUTH AMERICA; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TREATMENT DURATION; TUMOR RECURRENCE; UTERINE CERVIX CANCER; VACCINATION;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOADJUVANT THERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 68549085293     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24364     Document Type: Review

References (134)

1. Vizcaino AP, Moreno V, Bosch FX, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer. 2000;86:429-435. (Pubitemid 30187507)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, Md: National Cancer Institute; 2006.
4. Monk BJ, Sill M, McMeekin S, et al. A randomized phase III trial of 4 cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract LBA5504.
5. Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2007.
6. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
7. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-1143. (Pubitemid 29177872)
8. Peters WA III, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
9. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153. (Pubitemid 29177873)
10. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348. (Pubitemid 29220838)
11. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;(3):CD002225.
12. Wong LC, Ngan HY, Cheung AN, Cheng DK, Ng TY, Choy DT. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol. 1999;17:2055-2060. (Pubitemid 29318835)
13. Lorvidhaya V, Chitapanarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys. 2003; 55:1226-1232. (Pubitemid 36338288)
14. Domingo E, Lorvidhaya V, De Los Reyes R, et al. Capecitabine (X) and radiotherapy (RT) in locally advanced squamous carcinoma of the uterine cervix: phase II results [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 5513.
15. Chiara S, Bruzzone M, Merlini L, et al. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group). Am J Clin Oncol. 1994;17:294-297.
16. Leborgne F, Leborgne JH, Doldan R, et al. Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial. Int J Radiat Oncol Biol Phys. 1997;37:343-350. (Pubitemid 27138718)
17. Souhami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol. 1991;9:970-977.
18. Sundfor K, Trope CG, Hogberg T, Onsrud M, Koern J, Simonsen E, et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer. 1996;77:2371-2378.
19. Symonds RP, Habeshaw T, Reed NS, et al. The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. Eur J Cancer. 2000;36:994-1001. (Pubitemid 30316424)
20. Tattersall MH, Ramirez C, Coppleson M. A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs. radiotherapy alone in patients with locally advanced cervical cancer. Int J Gynecol Cancer. 1992;2:244-251.
21. Tattersall MH, Lorvidhaya V, Vootiprux V, et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol. 1995;13:444-451.
22. Herod J, Burton A, Buxton J, et al. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Ann Oncol. 2000;11:1175-1181. (Pubitemid 30783025)
23. Lacava JA, Leone BA, Machiavelli M, et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol. 1997;15:604-609. (Pubitemid 27074228)
24. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39:2470-2486.
25. Eddy GL, Manetta A, Alvarez RD, Williams L, Creasman WT. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1995;57:412-416.
26. Panici PB, Scambia G, Baiocchi G, et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. Cancer. 1991;67:372-379.
27. Benedetti RG, Heilman KJ III, Gabow PA. Nephrotoxicity following single dose mithramycin therapy. Am J Nephrol. 1983;3:277-278. (Pubitemid 14236009)
28. Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005;23: 4137-4145. (Pubitemid 46211319)
29. Chang TC, Lai CH, Hong JH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol. 2000;18:1740-1747. (Pubitemid 30220553)
30. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, et al. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol. 2001;12:541-547. (Pubitemid 32472112)
31. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol. 2007; 106:362-369.
32. Kigawa J, Minagawa Y, Ishihara H, Itamochi H, Kanamori Y, Terakawa N. The role of neoadjuvant intra-arterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer. Am J Clin Oncol. 1996;19:255-259. (Pubitemid 26160552)
33. Sugiyama T, Nishida T, Kumagai S, et al. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer. 1999;81:95-98. (Pubitemid 29415497)
34. Sugiyama T, Hasuo Y, Nishida T, Kamura T. Impact on survival following successful neoadjuvant chemotherapy and radical surgery for stage IIB bulky and stage IIIB cervical cancer. Gynecol Oncol. 2001;81:330-331. (Pubitemid 32424185)
35. Tanaka T, Kokawa K, Umesaki N. Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIB cervical squamous cell carcinoma: a pilot study. Eur J Gynaecol Oncol. 2005;26:605-607. (Pubitemid 43028052)
36. Termrungruanglert W, Tresukosol D, Vasuratna A, Sittisomwong T, Lertkhachonsuk R, Sirisabya N. Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2. Gynecol Oncol. 2005;97:576-581. (Pubitemid 40614906)
37. Benedetti-Panici P, Greggi S, Scambia G, et al. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer. 1998;34:341-346. (Pubitemid 28183831)
38. Long HJ III. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25:2966-2974. (Pubitemid 47123161)
39. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899-903. (Pubitemid 11049085)
40. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of 3 cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1079-1085. (Pubitemid 15004828)
41. Morris M, Gershenson DM, Burke TW, et al. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix. Gynecol Oncol. 1994;53:234-238. (Pubitemid 24177050)
42. Arseneau J, Blessing JA, Stehman FB, McGehee R. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group study). Invest New Drugs. 1986;4:187-191. (Pubitemid 16087374)
43. Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;90:177-180. (Pubitemid 37338094)
44. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-3119. (Pubitemid 41103724)
45. McQuellon RP, Thaler HT, Cella D, Moore DH. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:296-304.
46. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626-4633. (Pubitemid 46224065)
47. Brave M, Dagher R, Farrell A, et al. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park). 2006;20:1401-1404, 1410.
48. Wenzel LB, Huang H, Cella D, et al. Quality of life results of a randomized phase III trial of 4 cisplatin (Cis)-containing doublet combinations in stage IVB cervical carcinoma: a Gynecologic Oncology Group (GOG) study [abstract]. J Clin Oncol. 2008:26(May 20 suppl). Abstract 5529.
49. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105:299-303. (Pubitemid 46590319)
50. Dobrowsky W, Huigol NG, Jayatilake RS, et al. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cancer cervix: initial results of an IAEA multicentre randomized trial. J Cancer Res Ther. 2005;1:75-78. (Pubitemid 41265232)
51. Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:922-928. (Pubitemid 36794022)
52. Balsitis S, Dick F, Lee D, et al. Examination of the pRbdependent and pRb-independent functions of E7 in vivo. J Virol. 2005;79:11392-11402. (Pubitemid 41170680)
53. Kim GE, Kim YB, Cho NH, et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res. 2004;10:1366-1374.
54. Lee CM, Shrieve DC, Zempolich KA, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005;99:415-421.
55. Lee CM, Lee RJ, Hammond E, et al. Expression of HER2-neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol. 2004;93:209-214. (Pubitemid 38429572)
56. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol. 1993;46:149-153. (Pubitemid 23076346)
57. Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer. 1996;78:433-440.
58. Maruo T, Yamasaki M, Ladines-Llave CA, Mochizuki M. Immunohistochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. Cancer. 1992; 69:1182-1187.
59. Pfeiffer D, Stellwag B, Pfeiffer A, Borlinghaus P, Meier W, Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1989;33:146-150. (Pubitemid 19112903)
60. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999; 5:577-586.
61. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(suppl 4):S9-S15.
62. Mathur SP, Mathur RS, Young RC. Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol. 2000;44:222-230.
63. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer. 2003;39:1348-1354. (Pubitemid 36773776)
64. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265. (Pubitemid 34293391)
65. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol. 1993;67:4521-4532.
66. Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene. 2005;24:2585-2588. (Pubitemid 40593050)
67. Akerman GS, Tolleson WH, Brown KL, et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res. 2001;61:3837-3843.
68. Sizemore N, Choo CK, Eckert RL, Rorke EA. Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells. Exp Cell Res. 1998;244:349-356. (Pubitemid 28480883)
69. Hu G, Liu W, Mendelsohn J, et al. Expression of epidermal growth factor receptor and human papillomavirus E6/ E7 proteins in cervical carcinoma cells. J Natl Cancer Inst. 1997;89:1271-1276. (Pubitemid 27371947)
70. Goncalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108:42-46.
71. Erlich E, Carmo CC, Viegas C, et al. Erlotonib combined with cisplatin and radiotherapy for patients with locally advanced squamous cell cervical cancer: a phase II trial [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 5511.
72. Arias-Pulido H, Joste N, Chavez A, et al. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer. 2008;18:749-754. (Pubitemid 352020185)
73. Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol. 2007;106:513-520. (Pubitemid 47302461)
74. Kurtz E, Besson D, Deslandres M, et al. Cetuximab (Ce) + topotecan (Tc) + cisplatin (Cp) for the treatment (Tt) of advanced cervix cancer (ACC): a phase II GINECO trial [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 5512.
75. Van Custem, E, Lang, I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience [abstract]. J Clin Oncol. 2008;26(May 20 suppl), Abstract 2.
76. Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol. 2007;105:662-666.
77. Lee IJ, Park KR, Lee KK, Song JS, Lee KG, Lee JY, et al. Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 2002;54:768-779.
78. Lee JS, Kim HS, Park JT, Lee MC, Park CS. Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal Quant Cytol Histol. 2003;25:303-311. (Pubitemid 38044607)
79. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 2000;83:620-625. (Pubitemid 30636303)
80. Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh FJ, Hsieh CY. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol. 2000;96:721-726. (Pubitemid 30782526)
81. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103:489-493. (Pubitemid 44602157)
82. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res. 2002;89:183-190.
83. Wheeler CM. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol. 2007;4:224-235. (Pubitemid 46510532)
84. Wadler S, Levy D, Frederickson HL, et al. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol. 2004;92: 957-964.
85. Pohlmann P, DiLeone LP, Cancella AI, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol. 2002;25:496-501. (Pubitemid 35154957)
86. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005;4:22.
87. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354. (Pubitemid 40637826)
88. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-3310.
89. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268-5272. (Pubitemid 44497237)
90. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505-516. (Pubitemid 44036456)
91. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139-147.
92. Lhomme C, Vermorken JB, Mickiewicz E, et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer. 2000;36: 194-199. (Pubitemid 30102195)
93. Muggia FM, Blessing JA, Waggoner S, et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005;96:108-111. (Pubitemid 39612425)
94. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:792-795. (Pubitemid 26085522)
95. Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 1997;8: 657-661. (Pubitemid 27404721)
96. Goedhals L, van Wiyk AL, Smith BL, Fourie SJ. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer. 2006;16:1172-1178. (Pubitemid 43886742)
97. Ferrandina G, Lorusso D, Ludovisi M, et al. Phase II study on pemetrexd in advanced and/or recurrent cervical cancer patients: a MITO study. J Clin Oncol. 2008;26(suppl). Abstract 5515.
98. Meanwell CA, Mould JJ, Blackledge G, et al. Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep. 1986;70:727-730. (Pubitemid 16074181)
99. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15:625-631. (Pubitemid 27074231)
100. Lhomme C, Fumoleau P, Fargeot P, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1999; 17:3136-3142. (Pubitemid 29470643)
101. Look KY, Blessing JA, Levenback C, Kohler M, Chafe W, Roman LD. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 1998;70:334-338. (Pubitemid 28473631)
102. Takeuchi S, Dobashi K, Fujimoto S, et al. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers]. Gan To Kagaku Ryoho. 1991;18:1681-1689.
103. Muderspach LI, Blessing JA, Levenback C, Moore JL, Jr. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81:213-215.
104. Garcia AA, Blessing JA, Darcy KM, et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study. Gynecol Oncol. 2007;104:572-579.
105. Hirai Y, Katsumat N, Kamiura S, et al. Phase II study of S-1 in patients with advanced or recurrent cervical cancer [abstract]. J Clin Oncol. 2008.
106. Lorvidhaya V, Kamnerdsupaphon P, Chitapanarux I, Sukthomya V, Tonusin A. Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho. 2004;31:1057-1062.
107. Brewer CA, Blessing JA, Nagourney RA, McMeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100:385-388. (Pubitemid 43075274)
108. Matulonis UA, Campos S, Duska L, et al. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006;103:160-164. (Pubitemid 44374687)
109. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89: 402-407. (Pubitemid 36687783)
110. Muggia FM, Blessing JA, McGehee R, Monk BJ. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2004;94:483-487. (Pubitemid 39024557)
111. Gebbia V, Caruso M, Testa A, et al. Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix. Oncology. 2002;63:31-37. (Pubitemid 34977934)
112. Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3340-3344. (Pubitemid 41103691)
113. Goedhals L, Falkson G, Smith BL, et al. Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience. Anticancer Res. 2005;25: 2489-2492. (Pubitemid 41044737)
114. Papadimitriou CA, Sarris K, Moulopoulos LA, et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol. 1999; 17:761-766. (Pubitemid 29109303)
115. Wagenaar HC, Pecorelli S, Mangioni C, et al. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer. 2001;37:1624-1628. (Pubitemid 32778607)
116. Coleman RE, Clarke JM, Slevin ML, et al. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemother Pharmacol. 1990;27:52-54.
117. Smith HO, Jiang CS, Weiss GR, et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer. 2006;16:298-305.
118. Maluf FC, Leiser AL, Aghajanian C, et al. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer. 2006;16: 1165-1171. (Pubitemid 43886741)
119. Benjapibal M, Thirapakawong C, Leelaphatanadit C, Therasakvichya S, Inthasorn P. A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. Oncology. 2007;72:33-38. (Pubitemid 350249126)
120. Errihanni H, Elghissassi I, M'rabti H, et al. Phase II trial of capecitabine and cisplatin in advanced, persistent or recurrent carcinoma of the cervix. J Clin Oncol. 2008.26(suppl); 310s. Abstract 5574.
121. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol. 1990;37:354-358. (Pubitemid 20182980)
122. Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix. Eur J Gynaecol Oncol. 2003;24:323-326. (Pubitemid 36644624)
123. Nagao S, Fujiwara K, Oda T, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96: 805-809.
124. Secord AA, Havrilesky LJ, Carney ME et al. Weekly lowdose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol. 2007;12:31-36. (Pubitemid 46472550)
125. Verschraegen CF, Kavanagh JJ, Loyer E, et al. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001;92:2327-2333. (Pubitemid 33029076)
126. Tebbutt N, Rischin D, Quinn M, et al. A phase II trial of carboplatin and etoposide for relapsed or metastatic carcinoma of the cervix. Aust N Z J Obstet Gynaecol. 1998; 38:87-90. (Pubitemid 28077500)
127. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004;92: 635-638. (Pubitemid 38183155)
128. Umesaki N, Fujii T, Nishimura R, et al. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol. 2004;95:127-132. (Pubitemid 39286287)
129. Papadimitriou CA, Dimopoulos MA, Giannakoulis N, et al. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer. 1997;79:2391-2395. (Pubitemid 27251023)
130. van Lujik I, Coens C, van der Burg ME, et al. Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix. Ann Oncol. 2007;18:275-281. (Pubitemid 46323093)
131. Long HJ, III, Monk BJ, Huang HQ, et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;100:537-543.
132. Murad AM, Triginelli SA, Ribalta JC. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12:55-59. (Pubitemid 2029069)
133. Dimopoulos MA, Papadimitriou CA, Sarris K, et al. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol. 2002;85:476-482. (Pubitemid 34651888)
134. Choi CH, Kim TJ, Lee SJ, et al. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer. 2006;16:1157-1164. (Pubitemid 43886740)